Laboratory Synthesis Of Benserazide

Preparation of Benserazide

IUPAC name Benserazide CN: DL- serine 2- [(2 ,3 ,4- tri hydroxy phenyl )methyl ]hydrazide

Benserazide Use: antiparkinsonian (in combination with levodopa), decarboxylase inhibitor

Benserazide MW: 257.25 

Benserazide MF: C10H15N3O5

Benserazide monohydrochloride

MW: 293.71 MF: C10H15N3O5 · HCl
LD50: 5 g/kg (M, p.o.);5300 mg/kg (R, p.o.)

An off–white crystalline powder. M.p. 146° to 148°.Soluble 1 in 3 of water, 1 in 118 of ethanol, 1 in 66 of acetone, 1 in 180 of chloroform and 1 in 455 of ether.

Colour Tests.

Ammoniacal silver nitrate—black; p-Dimethyl–aminobenzaldehyde—red/-; Ferric chloride—green–brown; Folin–Ciocalteu reagent—blue; Methanolic potassium hydroxide—red; Millon's reagent—red–orange; Nessler's reagent—black; Palladium chloride—orange→brown; Potassium dichromate—brown.

Thin–layer Chromatography.

System TA—Rf 01; system TB—Rf 00; system TC—Rf 01; system TL—Rf 03; system TAE—Rf 7.

High Performance Liquid Chromatography.

System HX—RI 35.

Ultraviolet Spectrum.

Aqueous acid—203, 269 nm.

Reference(s):
Clarke's Analysis of Drugs and Poison
DE 1 165 607 (Roche; appl. 8.5.1962; CH-prior. 16.6.1961).
US 3 178 476 (Roche; 13.4.1965; CH-prior. 16.6.1961).
L-form:
US 3 557 292 (Roche; 19.1.1971; appl. 16.8.1968).
DE 1 941 284 (Roche; appl. 13.8.1969; CH-prior. 16.8.1968).
DAS 1 966 821 (Roche; appl. 13.8.1969; CH-prior. 16.8.1968).